Next Article in Journal
Selection of Fusarium Trichothecene Toxin Genes for Molecular Detection Depends on TRI Gene Cluster Organization and Gene Function
Next Article in Special Issue
Development and Characterization of Monoclonal Antibodies to Botulinum Neurotoxin Type E
Previous Article in Journal
Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic?
Article

Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays

1
Postgraduate Programme in Pharmaceutical Sciences; Federal University of Santa Maria, Santa Maria 97105-900, Brazil
2
Industrial Pharmacy Department, Federal University of Santa Maria, Santa Maria 97105-900, Brazil
*
Author to whom correspondence should be addressed.
Received: 22 November 2018 / Revised: 28 December 2018 / Accepted: 10 January 2019 / Published: 12 January 2019
(This article belongs to the Special Issue Characterization and Quantitative Analysis of Botulinum Neurotoxin)
Botulinum neurotoxin type-A (BoNTA) is one of the seven different serotypes (A to G) produced by Clostridium botulinum. A stability-indicating size-exclusion chromatography (SEC) method was developed and validated, and the specificity was confirmed by forced degradation study, interference of the excipients, and peaks purity. The method was applied to assess the content and high-molecular-weight (HMW) forms of BoNTA in biopharmaceutical products, and the results were compared with those of the LD50 mouse bioassay, the T−47D cell culture assay, and the reversed-phase chromatography (RPC) method, giving mean values of 0.71% higher, 0.36% lower, and 0.87% higher, respectively. Aggregated forms showed significant effects on cytotoxicity, as well as a decrease in the bioactivity (p < 0.05). The employment of the proposed method in conjunction with the optimized analytical technologies for the analysis of the intact and altered forms of the biotechnology-derived medicines, in the correlation studies, enabled the demonstration of the capability of each one of the methods and allowed for great improvements, thereby assuring their safe and effective use. View Full-Text
Keywords: botulinum neurotoxin type A; size-exclusion chromatography; reversed-phase chromatography; T−47D cell culture; LD50 mouse bioassay botulinum neurotoxin type A; size-exclusion chromatography; reversed-phase chromatography; T−47D cell culture; LD50 mouse bioassay
Show Figures

Figure 1

MDPI and ACS Style

Xavier, B.; Perobelli, R.F.; Walter, M.E.; da Silva, F.S.; Dalmora, S.L. Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays. Toxins 2019, 11, 35. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11010035

AMA Style

Xavier B, Perobelli RF, Walter ME, da Silva FS, Dalmora SL. Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays. Toxins. 2019; 11(1):35. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11010035

Chicago/Turabian Style

Xavier, Bruna, Rafaela F. Perobelli, Maurício E. Walter, Francielle S. da Silva, and Sérgio L. Dalmora 2019. "Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays" Toxins 11, no. 1: 35. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11010035

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop